Could TLT's NMBIC ACT leapfrog to SoC in China?Upon the successful - possibly early - conclusion of Ph2, and the FDA's nod to proceed to market, TLT will be in the driver's seat from a global perspective.
Few paid attention to the news in May that TLT's patents for both the laser and compound have been accepted by the Chinese Patent Office.
In contrast to the FDA, the Chinese Food and Drug Administration is far less onerous in terms of regulatory burden.
From what I've gathered, the Chinese might be receptive to promoting TLT's NMBIC ACT to Standard of Care. And that's without the need for a Ph3 trial as would be the case with the FDA.
Correct me if I'm wrong, but I don't think the United States Food and Drug Administration can dictate to the Chinese Food and Drug Administration which treatments qualify for highly coveted and highly lucrative SoC status.